The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT3 inhibitors, IDH inhibitors, and menin inhibitors. Menin inhibitors are currently being explored in several clinical trials, both as monotherapy and in combination with other agents.

In this podcast, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Ghayas Issa, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Ibrahim Aldoss, MD, City of Hope, Duarte, CA, and Aaron Goldberg, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, comment on the growing role of targeted agents in AML. The experts draw focus on the promise of menin inhibitors, highlighting findings from the AUGMENT-101 (NCT04065399) and KOMET-008 (NCT05735184) trials.